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Abstract
Immunization of pigs with a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine initially
elicits a weak interferon (IFN)-g response. To improve the immune response, an adjuvant consisting of plasmid encoding either
porcine interleukin (IL)-12 or IFN-awas co-administered during vaccination. In the presence of either adjuvant, at least a three-
fold increase in the primary virus-specific IFN-g response was observed. While this enhancement was only transient (1 week)
when the IL-12 expressing plasmid was used, the effect was not only still apparent at 6 weeks after vaccination in the presence of
the IFN-a expressing plasmid but even after challenge with a virulent genetically divergent PRRSV. In contrast, no effect of
either adjuvant on the production of anti-virus antibodies was noticed throughout the study. Despite the apparent augmentation
of a T helper (Th) 1 type response by the inclusion of IFN-a or IL-12 during vaccination, this modulation did not necessarily
correlate with a reduction in viremia. Since a similar increase in the degree of the IFN-g response to the PRRSV vaccine could be
achieved by substituting polyinosinic–polycytidylic acid in lieu of either cytokine, exposure to PRRSV in the presence of a
variety of Th 1 polarizing molecules can positively influence the development of the cell-mediated immune response of swine to
this pathogen. Conceivably, such intervention could be applied to improve the formulation of anti-PRRSV vaccines.
# 2004 Elsevier B.V. All rights reserved.
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1. Introduction
Porcine reproductive and respiratory syndrome
(PRRS) is an economically important disease of swine
characterized by abortion, stillbirth and weak-born
pigs. In its non-reproductive form, this syndrome
affects younger pigs more severely than older animals,
causing reduced growth and pneumonia that can be
made more severe by co-infection with other
pathogens (Thacker, 2003). The etiologic agent for
this disease is an RNA virus (PRRSV) that belongs to
the family Arteriviridae, which targets macrophages
for infection (Wensvoort et al., 1991; Collins et al.,
1992). PRRSV exhibits a significant degree of genetic
diversification (Murtaugh et al., 1998; Key et al.,
2001; Goldberg et al., 2003) and this characteristic
probably contributes to the difficulty in controlling
infectious outbreaks caused by it (Meng, 2000). Under
experimental conditions, the currently available
modified live virus (MLV) vaccine against this
pathogen has been shown to provide immunized pigs
adequate protection from subsequent challenge with
the homologous strain (Lager et al., 1997a, 1997b).
However, despite the demonstrated ability of this
vaccine to afford pigs partial protection against
infection by a genetically divergent PRRSV strain
(Osorio et al., 1998; Lager et al., 1999; Mengeling et
al., 2003a, 2003b), the overall protective immunity
provided to swine in commercial settings is generally
inadequate (Halbur, 2003).
Infection of pigs with wild type PRRSV (Nelson et
al., 1994; Loemba et al., 1996; Vezina et al., 1996;
Yoon et al., 1995; Albina et al., 1998b; Gonin et al.,
1999) or their vaccination with a live attenuated form
of this virus (Labarque et al., 2000; Ostrowski et al.,
2002) elicits an exuberant production of non-
neutralizing antibodies. In contrast, a transient T cell
mediated PRRSV-specific lymphoproliferative
response is detected at 4 weeks post-infection and
lasts an additional 9 (Bautista and Molitor, 1997) to 14
weeks (Lopez-Fuertes et al., 1999). Moreover, during
this time interval, limited quantities of IFN-g secreting
cells (SC) are also generated (Meier et al., 2003; Xiao
et al., 2004). Interestingly, in the absence of additional
antigenic stimulation this polarity reverses within the
ensuing 5 months, as manifested by a decreasing
antibody response and a gradual increase in the
intensity of the IFN-g response (Meier et al., 2003).
The initial antibody-dominated immune response is
not the result of insufficient antigenic stimulation,
since neither the inclusion of a commercial adjuvant
during primary vaccination (Meier et al., 2003) nor
booster immunizations of previously heavily vacci-
nated pigs (Bassaganya-Riera et al., 2004) enhances
virus-specific cell-mediated immunity (CMI). Thus,
PRRSV seems to inherently stimulate an imbalanced
immune response characterized by an abundance of
humoral immunity and a limited, but potentially
protective, Th 1-like IFN-g response (Murtaugh et al.,
2002).
One characteristic of PRRSV infection that
probably contributes to the retarded development of
a specific cell-mediated immune response is the lack
of induced IFN-a production (Albina et al., 1998a;
Buddaert et al., 1998; Van Reeth et al., 1999). Usually,
virus-infected cells secrete type I IFN and the released
cytokine interacts with a subset of naı¨ve T cells to
promote their conversion into virus-specific IFN-g SC
(Cella et al., 2000; Cousens et al., 1999; Kadowaki et
al., 2000; Biron, 2001; Levy et al., 2003). However, to
counteract a virus that is a poor inducer of type I IFN,
the development of a Th 1 response can be generated
by a pathway that utilizes interleukin (IL)-12
(Cousens et al., 1999; Biron, 2001). Indeed, the
injection of recombinant IL-12 (rIL-12) at the time of
vaccination and three additional times during the
following week enhanced the host cellular immune
response to PRRSV (Foss et al., 2002). Based on the
success of this intervention and the noted absence of
IFN-a generation during PRRSV infection, the present
studies were undertaken to determine if the antiviral
adaptive immunity induced by vaccination with PRRS
MLV could be modified simply by the co-adminis-
tration of rIL-12 protein directly, or of either porcine
IFN-a or IL-12 indirectly via plasmids expressing
these cytokines. In addition to these two elements that
can deliver Th 1 polarizing signals (Biron, 2001;
Kadowaki and Liu, 2002; Kapsenberg, 2003), the
effect of stimulation with a known inducer of IFN-a
production, namely double-stranded RNA, was exam-
ined. Although all three adjuvants positively influ-
enced the intensity and rate of development of the
virus-specific IFN-g response, the results indicate that
a stronger immunomodulator will be needed to
overcome the tendency of PRRSV not to elicit this
type of Th 1 response.
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2. Materials and methods
2.1. Viruses and cells
Prior to use for immunization, the Ingelvac PRRS
MLV vaccine (Boehringer Ingelheim Vetmedica Inc.,
St. Joseph, MO) was reconstituted from lyophilized
vials according to manufacturer’s instructions. The
highly virulent, ‘‘atypical’’ PRRSV strain IA-1-4-2
(97-7895, GenBank accession number AF325691)
was originally isolated from a severe case of
reproductive failure in an Iowa swine herd in 1996
(Osorio et al., 2002) and was used as the challenge
virus in the animal studies. The extent of nucleotide
sequence identity in ORF5 between this wild-type
strain and the parental strain of the vaccine (VR2332)
used in this study is approximately 91%. For
ELISPOT assays of PRRSV-specific IFN-g SC,
PRRSV strains VR-2332 (American Type Culture
Collection, Manassas, VA) and IA-1-4-2 were used as
sources of antigen. When required, PRRSV was
propagated and titrated in monolayers of MARC-145
cells as previously described (Meier et al., 2003).
Porcine peripheral blood mononuclear cells
(PBMC) were isolated from venous blood that had
been anti-coagulated with 5 mM heparin and the cells
were subsequently maintained as described by Meier
et al. (2003).
2.2. Mammalian expression vectors containing
porcine IFN-a or IL-12 cDNA
For generating a plasmid capable of expressing
IFN-a in mammalian hosts, an intact cDNA encoding
porcine IFN-a was first prepared by RT-PCR using
RNA isolated from pig lymphocytes previously
infected with pseudorabies virus (to stimulate IFN-
a production). Forward (TCTGCAAGGTTCCCAA-
TG) and reverse (GTCTGTCACTCCTTCTTCCTG)
primers were designed based on the nucleotide
sequence of porcine IFN-a cDNA (Lefevre and La
Bonnardiere, 1986). Products of the anticipated size
(590 bp) were cloned into the pCR12.1 plasmid
(Invitrogen Corp., Carlsbad, CA), and an insert having
the predicted restriction enzyme sites was sequenced.
A comparison of the coding region within the selected
amplicon to the previously reported IFN-a cDNA
revealed three nucleotide differences. These variations
resulted in two amino acid changes of a tyrosine to a
cysteine at position 109 and of an arginine to a leucine
at position 141 of the intact protein. The IFN-a cDNA
was then excised from the recombinant pCR12.1
plasmid and placed under the transcriptional regula-
tion of the cytomegalovirus promoter in pcDNA3
(Invitrogen) to generate pINA. To verify that an active
cytokine was encoded by the amplified cDNA,
Chinese hamster ovary (CHO) cells were transfected
with pINA and single cell clones resistant to 1.0 mg
geneticin per ml growth medium were prepared.
Supernatant medium from the clones were tested for
the ability to inhibit the replication of an interferon-
inducer negative strain of vesicular stomatitis virus
(Sekellick and Marcus, 1979) in Madin Derby bovine
kidney (MDBK) cells as previously described
(Rubinstein et al., 1981). Clones producing from 0
to greater than 200,000 units (1 unit inhibits 50% of
VSV replication in MDBK cell monolayers) of IFN-a
were detected.
For generating a plasmid capable of expressing a
composite IL-12 moiety consisting of the p35 and p40
subunits joined in tandem by an inert 15 amino acid
stretch in mammalian cells, cDNA encoding the 22
amino acid long leader region and 17 amino acids of
the mature form of the IL-12 p40 subunit was first
derived from plasmid p40–50 RACE #1 (provided by
Dr. M.P. Murtaugh, University of Minnesota) that
contains approximately the 50 half of IL-12 p40
subunit cDNA. This fragment was then inserted into
pcDNA3 and ligated to a segment that was excised
from the yeast expression plasmid pPic9scIL-12 (Foss
et al., 1999) and consisted of the remainder of the IL-
12 p40 subunit cDNA linked by a 45 nucleotide stretch
to cDNA encoding the mature form of the IL-12 p35
subunit. The resultant plasmid, pcPIL12, utilizes the
cytomegalovirus promoter to regulate expression of a
complete IL-12 complex consisting of one of each of
the two subunits. To verify that a biologically active,
secreted cytokine could be produced by pcPIL12,
CHO cells were either mock-transfected or transfected
with the plasmid and after 48 h the overlaying medium
was subjected to a bioassay designed to demonstrate
the presence of porcine IL-12 based on its ability to
increase the IFN-g response of memory T cells to
recall viral antigen (Meier et al., 2000). By
comparison to a yeast-derived porcine rIL-12 standard
(provided by Dr. M. Moody, Endogen, Woburn, MA),
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>100 ng/ml bioactive cytokine was found in the
transfected cell medium whereas no activity was
found to be associated with the control supernatant.
2.3. Large scale preparation of pINA and pcPIL12
Escherichia coli strain DH5a (Invitrogen) was
transfected with either pINA or pcPIL12 and grown in
1 L of LB medium supplemented with 100 mg/ml
ampicillin (Sigma, St. Louis, MO) for 16 h at 37 8C
with constant shaking (300 rpm). Plasmid purifica-
tion was conducted using a Qiagen Plasmid Maxi Kit
(Qiagen Inc., Valencia, CA) according to manufac-
turer’s instructions.
2.4. Preparation of cartridges for intradermal
biolistic delivery of cytokine cDNA
Plasmid pINA or pcPIL12 was precipitated onto the
surface of gold particles (average diameter of 5 mm;
Bio-Rad Laboratories, Inc., Hercules, CA) at a
concentration of 1.0 mg DNA/mg gold. Plastic tubing
was then coated with 0.5 mg of the DNA-bound gold
particles using a Tubing Prep Station (Bio-Rad)
following the manufacturer’s instructions and cut to
yield cartridges containing 0.5 mg DNA.
2.5. Reconstitution of porcine rIL-12
Immediately prior to use as a standard in the IL-12
bioassay or as an adjuvant in the animal studies,
lyophilized yeast-derived porcine rIL-12 (Endogen)
was reconstituted in low endotoxin-tested PBS
(Mediatech, Herndon, VA) to a concentration of
20 mg/ml.
2.6. Stabilization of polyinosinic:polycytidylic acid
(poly I:C)
Stabilized polyinosinic:polycytidylic acid (poly
I:C) was prepared by the method of Levy et al.
(1975) with minor modifications. Briefly, poly I:C
(Sigma) at 4 mg/ml in pyrogen-free 0.85% NaCl was
denatured at 71 8C for 1 h and allowed to re-anneal
while cooling slowly to ambient temperature. The
annealed poly I:C solution was then mixed with equal
volumes of 6.0 mg poly-L-lysine/ml pyrogen-free
0.85% NaCl and 2% carboxymethylcellulose in
pyrogen-free 0.85% NaCl. The final preparation
was stored at 4 8C until needed.
2.7. PRRSV vaccination and challenge of pigs
In the first study, 9-week-old Yorkshire x Landrace
cross-bred pigs were obtained from a PRRSV-free
herd and randomly segregated into five groups (n = 5)
and a sixth group of only two individuals. The latter
group was kept in a PRRSV-free environment and was
not vaccinated or challenged. All other animals were
immunized in their adductor muscles (inner thigh)
with 2.0 ml of Ingelvac PRRS MLV vaccine. At the
same time, some of the pigs were inoculated
intramuscularly (i.m.) by needle with either 2 ml of
saline (group 1), 200 mg pINA (group 2) or pcPIL12
(group 3) per animal or intradermally (i.d.) with 5 mg
of pcPIL12/animal (group 4) via biolistic delivery
with a gene gun (Bio-Rad) at locations adjacent to the
site of vaccination. Twenty micrograms of porcine
rIL-12 in a 2 ml volume were co-administered to the
members of group 5, which also received a second i.m.
injection of the cytokine 24 h later. At 8 weeks post-
immunization, all pigs receiving only the vaccine
except one (group 1), or the vaccine in conjunction
with an i.m. application of either plasmid pINA (group
2) or pcPIL12 (group 3) were transferred to a bio-
containment facility together with five additional
PRRSV-naı¨ve pigs (group 7) obtained from the same
herd mentioned above. At this time all of the
transferred animals were challenged with
105.8 TCID50/2.0 ml (1.0 ml/nostril) of PRRSV strain
IA-1-4-2. Fourteen days later all pigs were euthanized.
For the second study, twelve 6-week-old Yorkshire
 Landrace cross-bred pigs were obtained from the
same PRRSV-free herd described above and were
randomly assigned to one of two groups (n = 6). While
all pigs were immunized i.m. with 2.0 ml of Ingelvac
PRRS MLV vaccine, 0.25 mg poly I:C/kg of body
weight was co-administered to the animals of one
group only. This dose of poly I:C was selected based
on its demonstrated ability to induce the maximum
presence of IFN-a in the sera of 10-week-old pigs
(Loewen and Derbyshire, 1988). Pigs were bled at 6,
12, 24 and 48 h after poly I:C administration and
differential white blood cell numbers were determined
with a Cell-Dyne 3500 (Abbott Laboratories, Abbott
Park, IL) and confirmed by microscopy by an
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experienced technician. Eight weeks later, members of
both groups were given a secondary ‘‘booster’’
immunization identical in composition to that of the
primary vaccination.
2.8. Quantitation of the anti-PRRSV cell-mediated
and humoral cellular immune responses of
vaccinated pigs
The extent of the host cell-mediated immune
response to PRRSV was measured by using a single
cell ELISPOT assay (Mateu de Antonio et al., 1998;
Meier et al., 2003) to enumerate virus-specific IFN-g-
SC in the PBMC population. The presence of PRRS
virus-neutralizing (VN) antibodies in the sera was
determined as previously described by Benfield et al.
(1992). Briefly, twofold serial dilutions of serum
(100 ml) in modified Eagle’s minimal essential
medium (MEM) were mixed with an equal volume
of MEM containing 300 TCID50 of the selected
PRRSV strain. After incubation at 37 8C for 1 h, the
mixture was added to monolayers of MARC-145 cells
in 96-well tissue culture plates. The cells were then
examined daily during a 7-day interval, and the end
point titer was expressed as the reciprocal of the
highest serum dilution that neutralized the develop-
ment of a PRRSV-induced cytopathic effect.
Quantities of non-neutralizing PRRSV-specific
antibodies in the sera were measured by using a
commercial ELISA assay (Herd-Chek PRRS, IDEXX,
Westbrook, ME). Sample to positive (S/P) ratios
greater than 0.4 were considered positive and were
calculated based on the manufacturer’s instructions
utilizing the formula: S/P = (test sample A(650)
against PRRSV antigen  test sample A(650) against
normal host cell antigen)/(positive control against
PRRSVantigen positive control against normal host
cell antigen).
2.9. Evaluation of the anti-PRRSV protection
afforded to vaccinated pigs
Virus was detected in serum samples collected on
days 4, 7 and 11 post-PRRSV challenge and from
tonsil biopsies obtained at the termination of the
experiment. Prior to use, tonsils (0.2 g) were first
homogenized by grinding the tissue with a pestle in a
1.5 ml microfuge tube, adding 500 ml of MEM
supplemented with 50 mg of gentamicin per ml, and
vigorously shaking the sample with the pestle in the
tube. After removal of the pestle, an additional 500 ml
of MEM was added, and the homogenate was again
mixed vigorously. The suspension was then passed
through a 0.20 mm pore-size filter and stored at
20 8C.
To detect infectious PRRSV, quadruplicate sets of
MARC-145 cell monolayers in 12- or 24-well plates
were incubated with either 300 ml of serial 10-fold
dilutions of serum or tonsil homogenate (starting with
1:2 dilution) in MEM supplemented with 50 mg of
gentamicin per ml for 1 h at 37 8C in 5% CO2.
Afterwards, the inocula were removed and replaced
with 1 ml MEM supplemented with 3% fetal calf
serum and 50 mg of gentamicin per ml. The cells were
then incubated for 7 days at 37 8C and checked daily
for signs of cytopathic effect.
2.10. Statistical analyses
Results are expressed as the mean  the standard
error of the mean (S.E.). Statistical significance was
determined by analysis of variance. When significant
differences at the 0.05% confidence level were
present, individual differences between treatment
groups were determined with Fisher’s protected least
significant difference (PLSD). The comparison
between the quantity of virus in sera and tonsils
was done by using the Fisher’s exact test. The analyses
were performed with the Statview program V4.5
(Abacus Concepts, Berkeley, CA).
3. Results
3.1. Anti-PRRSV cell-mediated immune response in
pigs vaccinated in the absence/presence of IFN-a or
IL-12
Immunization of pigs with only PRRS MLV
vaccine induced a relatively mild CMI response
during the ensuing 6 weeks as evidenced by the low
frequency of PRRSV-specific IFN-g SC in the
vaccinated pigs’ PBMC populations (Fig. 1).
Although a similar response was evident during this
time period for vaccinated pigs also i.m. injected with
exogenous IL-12 either directly as protein or
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indirectly via IL-12 cDNA, immunized animals that
were i.d. inoculated with IL-12 cDNA exhibited an
overall 2.7-fold transient increase in the frequency of
PRRSV-specific IFN-g SC at 2 weeks post-vaccina-
tion. Likewise, a slightly greater enhancement of
three-fold was found in those vaccinated animals that
had received IFN-a cDNA. However, in this case, the
IFN-g response remained elevated at about this extent
throughout the following 4 weeks.
Since the pigs immunized with PRRSV MLV in the
presence of pINA exhibited a significantly enhanced
and sustained IFN-g response as compared to those in
the other vaccinated groups, these animals as well as
those receiving the vaccine only or the vaccine plus an
i.m. injection of pcPIL12 were transferred to a bio-
containment facility and challenged with PRRSV
strain IA-1-4-2. As controls, an additional group of
age matched PRRSV-naı¨ve pigs were included and
also infected with the virulent virus. During the 2
weeks after challenge, the animals originally immu-
nized in the presence of IFN-a cDNA continued to
display a statistically significant, greater IFN-g
response relative to that measured in the other pigs.
3.2. Anti-PRRSV humoral immune response in pigs
vaccinated in the absence/presence of IFN-a or IL-12
All MLV-vaccinated pigs exhibited strongly posi-
tive anti-PRRSV antibody titers (S/P ratios ranged
from 0.8 to 1.75) at 2 weeks following immunization
and their levels of humoral immunity had increased
when measured 2 weeks later (S/P ratios ranged from
1.3 to 2.2) (Fig. 2). However, there were no significant
differences between the mean S/P ratios of the cohort
receiving the vaccine alone and of any of those groups
whose vaccination was supplemented with a cytokine
adjuvant. In contrast, VN antibodies were not detected
until 4 weeks after immunization and then only at low
titers (1:4; v:v) and in at most one or two pigs per
group (Table 1). Differences between the various
cohorts in regards to the proportion of pigs that
contained VN antibodies were not found to be
significant. Immediately prior to challenge with the
virulent PRRSV IA-1-4-2 strain at 8 weeks post-
vaccination, VN antibodies were not detected in serum
collected from any member of the three cohorts being
challenged (MLV only, MLV + pcPIL12 i.m., and
MLV + pINA i.m.; Fig. 3). Although subsequently by
2 weeks post-challenge the majority of the pigs had
developed a detectable VN antibody response, the
three groups could still not be statistically differ-
entiated based on their average VN titers. Despite use
of the challenge strain in lieu of PRRSV isolate VR-
2332 as an antigen source appearing to result in a
slightly more sensitive assay for the presence of VN
antibody, this visual difference was determined not to
be statistically significant. As expected due to the short
interval between exposure to virus and performance of
the assay, PRRSV-neutralizing antibodies were not
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Fig. 1. Comparison of the intensities of the virus-specific IFN-g SC
response of pigs to immunization with a PRRS MLV vaccine in the
absence/presence of IL-12 or IFN-a. Groups of pigs were vaccinated
with PRRS MLV alone (group 1) or also received i.m. injections of
plasmid expressing porcine IFN-a (group 2) or IL-12 (group 3), i.d.
injections of plasmid expressing porcine IL-12 (group 4), or 2 i.m.
injections of porcine rIL-12 at a daily interval (group 5). An
additional group served as unvaccinated controls (group 6). At 8
weeks post-immunization, vaccinated animals in groups 1–3 as well
as five, newly acquired PRRSV-naı¨ve pigs (challenge control, group
7) were challenged with PRRSV strain IA-1-4-2. PBMC were
isolated from the pigs at the indicated times post-vaccination and
the presence of virus-specific IFN-g SC was determined by using an
ELISPOT assay. Asterisks indicate significant differences
(P < 0.05) between the frequencies of IFN-g SC in the blood of
the animals immunized with the MLValone as compared to the other
immunized groups. Each value represents the mean response of five
animals  S.E.M. except for group 1 that was downsized to four
pigs immediately prior to challenge and group 6 that consisted of
two animals.
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Fig. 2. Comparison of the intensities of the virus-specific humoral
immune response of pigs to immunization with a PRRS MLV
vaccine in the absence/presence of IL-12 or IFN-a. Serum was
drawn from all members of groups 1–6 described in the legend to
Fig. 1 and assayed for the presence of anti-PRRSV antibodies.
Results are presented as sample to positive (S/P) ratios with a
cut-off of 0.4. Each value represents the mean S/P ratio obtained
for five animals  S.E.M. except for the control group consisting of
two animals.
Table 1
Comparison of the presence of PRRSV-neutralizing antibodies in the serum of pigs after immunization with a PRRSV MLV vaccine in the
absence/presence of IL-12 or IFN-a
Group no.a Treatment Number of VN antibody positive pigs/total pigsb (weeks after vaccination)
0 1 2 4 8
1 MLV 0/5 0/5 0/5 1/5 0/4
2 MLV + IFN-a cDNA i.m. 0/5 0/5 0/5 0/5 0/5
3 MLV + IL-12 cDNA i.m. 0/5 0/5 0/5 1/5 0/5
4 MLV + IL-12 cDNA i.d. 0/5 0/5 0/5 1/5 NDc
5 MLV + rIL-12 protein i.m. 0/5 0/5 0/5 2/5 ND
6 Unvaccinated 0/2 0/2 0/2 0/2 ND
a Serum was drawn from all members of groups 1–6 described in the legend for Fig. 1 at the indicated times after vaccination and assayed for
the presence of virus neutralizing (VN) antibodies against PRRSV isolates VR2332 and IA-1-4–2.
b The numerator values represent the number of VN positive pigs, and the denominator values represent the total number of pigs in each
respective group. The VN titer in positive samples was 1:4 against either virus isolate.
c Not done.
Fig. 3. Comparison of the presence of PRRSV-neutralizing anti-
bodies in the serum of vaccinated pigs after a challenge with wild
type PRRSV. Immediately prior to and 2 weeks after challenge with
PRRSV strain IA-1-4-2, serum was drawn from four members of
group 1 and all pigs in groups 2, 3 and 7 described in the legend to
Fig. 1 and assayed for the presence of PRRSV-neutralizing anti-
bodies. Results are presented as the reciprocal of the lowest two-fold
dilution of serum that inhibited the replication of either PRRSV
strain VR-2332 or IA-1-4-2 in MARC-145 cell monolayers. Each
value represents the mean PRRSV neutralizing antibody titer in the
blood of five animals  S.E.M. except for group 1 that was down-
sized to four pigs immediately prior to challenge.
detected in the sera of the challenged, non-vaccinated
pigs.
3.3. PRRS viremia in pigs vaccinated in the absence/
presence of IFN-a or IL-12
At 4 days post-PRRSV challenge, one of four pigs
immunized with MLV vaccine alone (group 1) and
three of five pigs immunized in conjunction with an
i.m. injection of pcPIL12 (group 3) had detectable
viremia (level of sensitivity102.2 TCID50/ml serum)
(Fig. 4). In contrast, at this time all of the unvaccinated
pigs (group 7) and all of those that received pINA in
combination with the vaccine were viremic (group 2).
Three days later, only three of the five animals injected
with pINA (group 2) as well as all of the non-
immunized pigs (group 7) remained viremic (level of
sensitivity 101.2 TCID50/ml serum). By 11 days
post-challenge, virus could be found in the serum of
only one of the unvaccinated pigs and none of the
vaccinated pigs (level of sensitivity101.2 TCID50/ml
serum). PRRSV was also detected in the tonsils of
three of the five non-immunized animals, but not in
biopsies removed from any of the vaccinated pigs,
when the experiment was terminated at 14 days after
challenge (level of sensitivity 102.2 TCID50/g tis-
sue). The lower sensitivity of the virus detection assay
at 4 days after challenge was due to the toxicity of the
serum at a 1:10 dilution. This toxic effect was not
present in the serum samples collected 7 or 11 days
after challenge.
3.4. Anti-PRRSV cell-mediated and humoral immune
responses in pigs vaccinated in the absence/presence
of poly I:C
To evaluate the impact of poly I:C on the host
response to PRRSV, the immune status of pigs
receiving the MLV vaccine alone or in conjunction
with this synthetic double-stranded RNA and then
revaccinated with the same formulations 8 weeks later
was monitored for a total of 11 weeks. A nearly
immediate effect of poly I:C on the pigs was observed
as evidenced by an approximately 50% reduction in
the quantity of white blood cells in their peripheral
blood as compared to the other animals at 6 h after the
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Fig. 4. Comparison of the virus titers in the sera and tonsils of vaccinated pigs after a challenge with wild type PRRSV. Serum was drawn from
four members of group 1 and all pigs in groups 2, 3 and 7 described in the legend to Fig. 1 at 4, 7 and 11 days post-challenge with PRRSV strain
IA-1-4-2, while tonsil biopsies were obtained at 14 days after challenge for all virus-challenged pigs. Virus titers (log10 TCID50 per ml of serum
or per gram of tonsil) are presented for each pig (circle). The limit of detection for each assay is indicated by the dotted line and values at this level
have been placed on the line. Bars indicate the mean of four or five measurable titers within a group. Statistical significance (P < 0.02, P < 0.05)
is based on differences on the percent of viremic pigs between the indicated treatment groups as determined by Fisher’s exact test.
administration of this compound. This leukopenia was
transient as it was no longer apparent 42 h later (data
not shown). At 1 week post-immunization, the poly
I:C-treated pigs also exhibited a significant 7.3-fold
increase in the frequency of their PRRSV-specific
IFN-g SC as compared to the untreated pigs (Fig. 5).
This enhancement tapered off but was still >2-fold
when measured 1 and 2 weeks later. From then until
the time of the second immunization, significant
differences between the frequencies of the IFN-g SC
in the two groups were not detected. However, 1 week
after the booster immunization, once again the
frequency of virus-specific IFN-g SC in the poly
I:C-treated animals increased in comparison to the
untreated animals—in this case a statistically sig-
nificant 2.2-fold. During the ensuing 2-week interval
until the termination of the experiment, no differences
between the two groups in regards to this parameter
were observed. Although PRRSV-specific antibodies
were readily detected in all of the pigs’ sera when
collected at 10 and 11 weeks post-primary immuniza-
tion, no significant differences were found to exist
between the average antibody titers of the poly I:C-
treated and untreated groups (data not shown).
4. Discussion
The data presented here demonstrate the adjuvant
effects of IFN-a when provided exogenously in the
form of an expressible cDNA (pINA) or circuitously
via induction of IFN-a synthesis (poly I:C) on the
vaccine-induced IFN-g response to PRRSV. However,
despite the positive modulation of Th 1 immunity, no
significant alteration in the development of the
humoral immune response was observed. Thus, even
with such intervention at the initiation of PRRSV
immunization, the usual rapid onset of anti-PRRSV
antibody production and delayed appearance of VN
antibodies (Labarque et al., 2000; Ostrowski et al.,
2002; Meier et al., 2003) still occurred. Although in
previous studies a similar increased presence of
PRRSV-specific IFN-g SC was afforded to pigs
receiving multiple injections of IL-12 at the time of
vaccination and during the ensuing week (Foss et al.,
2002), the use of a conventional oil-in-water adjuvant
was found to be ineffective in this regard (Meier et al.,
2003). Moreover, in that study, even though this
compound demonstrably enhanced the genesis of VN
antibodies recognizing pseudorabies virus in addition
to specific IFN-g SC, the intensity of either type of
immune response to PRRSV was not affected.
Apparently PRRSV possesses inherent structural
elements that prevent the timely development of
protective innate or adaptive immunity capable of
inhibiting its infectious process. Thus, the ultimate
outcome of the interaction between this virus and its
host will be determined by the elicited host response
which is highly variable, as evidenced by the
inconsistency of the clinical outcomes seen upon
challenge of naı¨ve or immune pigs with PRRSV
(Labarque et al., 2003; Mengeling et al., 2003a,
2003b). This is likely due to the significant variability
within the swine population in regards to their innate
and adaptive immune responses to PRRSV (Xiao et
al., 2004; Royaee et al., 2004).
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Fig. 5. Comparison of the intensities of the virus-specific IFN-g SC
response of pigs to immunization with a PRRS MLV vaccine in the
absence/presence of poly I:C. Groups of pigs were vaccinated with
PRRS MLV alone or in conjunction with poly I:C at an 8-week
interval. PBMC were isolated from the pigs at the indicated times
post-vaccination and the presence of virus-specific IFN-g SC was
determined by using an ELISPOT assay. Significant differences
(P < 0.05) between the frequencies of IFN-g SC in the blood of
the two groups are indicated by an asterisk. Each value represents
the mean response of six animals  S.E.M.
The ability of PRRSV to not initially elicit
protective immunity in an infected host is relatively
novel among viruses that even after being inactivated
can usually still promote a Th 1-like response (de Wit
et al., 2004). In this regard it is notable that the IFN-a
response to exposure to PRRSV is nearly non-existent.
For example, IFN-a production in the lungs of pigs
acutely infected with PRRSV was either almost
undetectable, or 159-fold lower than that induced by
another pathogen, porcine respiratory coronavirus
(PRCV) (Buddaert et al., 1998; Van Reeth et al.,
1999). Such lack of efficient stimulation of IFN-a
production by a pathogen has a significant impact on
the nature of the host’s adaptive immune response,
since IFN-a up-regulates IFN-g gene expression, and
thus controls the dominant pathway that promotes the
development of adaptive immunity, namely, T cell-
mediated IFN-g responses and peak antiviral immune
defenses (Cousens et al., 1997; Levy et al., 2003). In
this regard, it has become evident that the link between
innate and adaptive immunity in viral infections
occurs through the interaction of dendritic cells with
type I interferon (Montoya et al., 2002; Tough, 2004)
and the dendritic-cell controlled polarization of T-cell
function (Kapsenberg, 2003). The production of IFN-
a by plasmacytoid dendritic cells/natural IFN-a/b-
producing cells (NIPC) has an autocrine effect that
promotes their functional and phenotypic activation,
which is necessary for their optimal expression of co-
stimulatory molecules and subsequent ability to cause
naı¨ve T cells to differentiate into IFN-g-SC (Cella et
al., 2000; Kadowaki et al., 2000; Fitzgerald-Bocarsly,
2002; Montoya et al., 2002; Honda et al., 2003).
Presumably, PRRSV is a poor inducer of IFN-a
production by NIPCs since unlike transmissible
gastroenteritis virus (Charley and Lavenant, 1990;
Nowacki et al., 1993) and type-A CpG oligonucleo-
tides (Guzylack-Piriou et al., 2004) it fails to stimulate
the secretion of IFN-a from cultured porcine PBMC
(Albina et al., 1998a; Zuckermann et al., unpublished
observations). Thus, direct examination of the out-
come of the interaction of PRRSV with porcine NIPCs
will likely reveal important information on the
immunobiology of this virus, especially since this
virus is susceptible to the antiviral effects of IFN-a
(Albina et al., 1998a). The application of molecular
tools such as real-time PCR assays to measure the
expression of key immune mediators that regulate the
development of Th 1 responses in swine (Dawson et
al., 2004) will be particularly useful in this endeavor.
It should be noted that in the absence of IFN-a/b
production, the cytokine IL-12 whose synthesis is not
induced by most viral infections (Orange and Biron,
1996) can increase IFN-g production by T cells
(Cousens et al., 1999). Thus, two alternative routes
(IL-12- or type I IFN-dependent) can lead to an
adaptive Th 1 cell-mediated immune response with
potent antiviral effects (Biron, 2001). According to a
scenario involving the presence of less than a requisite
amount of IFN-a, IL-12 could provide the necessary
impetus for the development of an anti-viral IFN-g
response. In this regard, IL-12 mRNA has been
detected in porcine macrophages infected with
PRRSV (Thanawongnuwech et al., 2001), and
transiently in the lungs of PRRSV-infected pigs
(Chung and Chae, 2003). However, this pathogen is
also apparently a poor stimulator of IL-12 production,
since a negligible quantity of IL-12 mRNA or protein
was produced by porcine PBMC exposed in vitro to
PRRSV (Royaee et al., 2004; Zuckermann et al.,
unpublished observations). The observation that the
inclusion of either IL-12 and IFN-a during immuniza-
tion increased the intensity of the IFN-g response to
PRRSV validates the proposed role of these two innate
cytokines in directing the in vivo differentiation of
swine Th 1 cells, and helps explain the poor virus-
specific IFN-g response that normally develops as a
result of the exposure of pigs to PRRSV (Meier et al.,
2003; Xiao et al., 2004).
To compensate for the lack of stimulation of innate
cytokine expression by PRRSV, novel adjuvants have
been used during immunization. The administration of
IL-12 in combination with a live or killed PRRSV
vaccine resulted in an increased lymphoproliferative
response to this virus (Wee et al., 2001). Inclusion of
either a combination of IL-1 and IL-6 or cholera toxin
correlated with an enhanced response to PRRSV but
only at 6 weeks after the initial exposure (Foss et al.,
2002). Moreover, in that study, the frequency of virus-
specific IFN-g SC did transiently increase between 2
and 3 weeks post-vaccination of pigs also injected
with porcine rIL-12. Although similar results were
obtained in the current study, albeit after biolistic
injection of expressible IL-12 cDNA in lieu of protein,
the provision of IFN-a cDNA had a more pronounced
and sustained effect on the intensity of the cell-
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mediated immune response. It was notable that the i.d.
administration of IL-12 cDNA with a gene gun was
more successful at enhancing the vaccine-induced
IFN-g response than the i.m. injection of the same
plasmid. This observation is in agreement with the
reported higher efficiency of in vivo DNA transfection
by biolistic delivery (Fynan et al., 1993; Colosimo et
al., 2000). The greater effectiveness of the plasmid
encoding IFN-a rather than IL-12 at enticing an IFN-g
response could be attributed to the relatively low
amounts of complete IL-12 receptor on swine
lymphocytes and the limited up-regulation of expres-
sion of the IL-12 receptor ß2 subunit gene as
compared to other species (Solano-Aguilar et al.,
2002). In this regard, it should be noted that the
injection of bioactive IL-12 into naı¨ve pigs did not
stimulate a strong T cell response (Solano-Aguilar et
al., 2002). Likewise, the introduction of a known
inducer of IFN-a production in pigs, poly I:C
(Derbyshire and Lesnick, 1990), during vaccination
temporarily amplified the quantities of PRRSV-
specific IFN-g SC, but was not as efficient as the
IFN-a encoding plasmid at enhancing the IFN-g
response to the vaccine. This difference could be
attributed to the presence of immunostimulatory CpG
motifs in the eukaryotic expression vector pcDNA3,
which was used in this study to express the cytokine
genes, and has been shown to induce IFN-g expression
by porcine leukocytes (Magnusson et al., 2001). It is
plausible that the combination of direct stimulation of
NIPC by the CpG motifs in the IFN-a-encoding
plasmid, presumably through their toll-like receptor 9
(Shimosato et al., 2003), in combination with the
plasmid-driven production of IFN-a would provide
the necessary stimulatory signals to promote the
maturation of dendritic cells and the creation of a
microenvironment conducive for a sustained IFN-g
response to PRRSV. Although poly I:C induces IFN-a
production, it does not entice porcine NIPC to
differentiate (Guzylack-Piriou et al., 2004), and thus
might not provide enough impetus to promote a
sustained T-cell-mediated IFN-g response to this
virus. This notion is in agreement with the role
attributed to CpG-containing oligonucleotides in
promoting the maturation of NIPC in humans (Krug
et al., 2001) and swine (Guzylack-Piriou et al., 2004).
The inability of IFN-a cDNA to enhance the VN
antibody response to PRRSV is in contrast to the
positive effect exerted by the co-administration of
adenovirus expressing IFN-a in combination with a
foot-and-mouth disease virus (FMDV) subunit vac-
cine into pigs (Chinsangaram et al., 2003; Moraes et
al., 2003). The notion of an structural inherent
property unique to PRRSV that deters the elicitation
of a strong VN antibody response is in accord with the
observation that in the case of PRRSV-neutralizing
antibodies, the close association of a nearby N-glycan
with a recognized epitope in the virus’s envelope
glycoprotein 5 may impede neutralization of this virus
(Plagemann et al., 2002). In addition, decoy epitopes
that delay the development of VN antibodies also exist
(Ostrowski et al., 2002). Remarkably, as we have
shown here, the titer of VN antibodies increased
equally in all vaccinated groups as a result of the pigs
being challenged with a genetically divergent, virulent
virus. Similarly, augmented titers of VN antibodies
against PRRSV have been observed in pigs previously
vaccinated with PRRS MLV after they received a
booster immunization with an inactivated genetically
divergent virus but not when exposed to the same
attenuated virus (Osorio et al., 1998; Bassaganya-
Riera et al., 2004).
As compared to the control (PRRSV naı¨ve) pigs, a
lower proportion of those vaccinated with PRRS MLV
exhibited viremia at 4 and 7 days after challenge.
However, no further reduction was observed in
animals also receiving either IL-12 or IFN-a. Rather,
injection of pINA increased the percentage of viremic
pigs, although the mean virus titer in their sera was
intermediate between those values determined for the
vaccinated and un-vaccinated groups at 4 days after
challenge. The significance of this observation with
regards to protective immunity is unclear. This is due
to the fact that while vaccination can decrease the
duration and magnitude of viremia following an
experimental challenge (van Woensel et al., 1998;
Verheije et al., 2003), the reduction in viremia is not
necessarily associated with commensurate ameliora-
tion of the severity of other clinical parameters
associated with PRRS such as a lessened rate of
weight gain, fever, respiratory distress or virus
transmission to sentinel pigs (Nodelijk et al., 2001;
Labarque et al., 2003; Mengeling et al., 2003a). A
similar lack of correlation between viremia and
clinical signs was also noted when two different
age groups of non-immune pigs were infected with
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PRRSV. Whereas a greater frequency of viremia with
an accompanying higher virus titer was found in the
younger animals (2 months of age), the older pigs (6
months of age) exhibited more severe clinical signs
(van der Linden et al., 2003). The difficulty of
deciphering PRRSV biology is further revealed by the
marked degree of variability and irreproducibility of
consecutive trials conducted by the same investigators
(Labarque et al., 2003; Mengeling et al., 2003a,
2003b). Moreover, although a positive association
between protection from disease and the intensity of
the IFN-g response in swine has been observed in
regard to pseudorabies virus (Zuckermann et al., 1998,
1999; Van Rooij et al., 2004), a similar relationship
concerning PRRSV was not apparent from the results
of this study. Thus, the identification of an immuno-
logic mechanism responsible for mediating protective
immunity against PRRSV poses a significant chal-
lenge and will perhaps require monitoring the extent
of reproductive failure caused by this virus as a
measurement of the degree of protection (Lager et al.,
1999). Notably, in recent, related field studies we have
noticed a positive correlation between the reduction of
abortion/still births in sows and the relative frequency
of PRRSV-specific IFN-g SC in their blood (Lowe et
al., 2004). In any event, perhaps a more marked
enhancement of the vaccine-induced IFN-g response
will be needed in order to improve protective
immunity against PRRSV as we found to be the case
when IL-12 was used as an adjuvant for an inactivated
pseudorabies virus vaccine, which like the PRRS
MLV vaccine stimulates a weak IFN-g response
(Zuckermann et al., 1998).
Clearly, further studies will be required to clarify
how the outcome of a PRRSV infection is influenced
by the intensity of the IFN-g response by memory T
cells. Nevertheless, the potential importance of
eliciting a strong IFN-g response against this pathogen
might not be limited to preventing virus replication
(Bautista and Molitor, 1999; Rowland et al., 2001).
Since IFN-g can restrain B cell differentiation and
even polyclonal B cell activation (Cowdery and
Fleming, 1992), it is reasonable to propose that a
strong IFN-g response could mediate protective
immunity by thwarting the polyclonal B cell activation
that is associated with PRRSV infection and results in
immunopathology (Lemke et al., 2004). The uncon-
trolled B cell activation induced by PRRSV could also
contribute to the observed weak cell-mediated
immune response, since activated B cells can release
IL-10 (Burdin et al., 1997), a cytokine that inhibits
both IFN-g production by porcine T cells (Waters et
al., 1999), and IFN-a synthesis by human PBMC in
response to viral stimulation (Payvandi et al., 1998). In
the accompanying manuscript (Royaee et al., 2004)
we demonstrate that PBMC obtained from pigs at 2
weeks after immunization with PRRS MLV sponta-
neously secrete IL-1, IL-6, and IL-10 and that the
production of these cytokines are indeed affected by
the administration, at the time of vaccination, of the
same IFN-a expressing plasmid utilized in the present
study. Such repression may be critical since unabated
PRRSV infection will actually stimulate synthesis of
IL-6 (Asai et al., 1999), a known inhibitor of Th 1 cell
development (Diehl and Rincon, 2002) and promoter
of polyclonal immunoglobulin production following B
cell activation by the murine arterivirus, lactate
dehydrogenase-elevating virus (Markine-Goriaynoff
et al., 2001).
Strategies designed to shift the bias of the initial
reaction to PRRSV from the strong elicitation of non-
neutralizing antibody production towards a greater Th
1-like immune response are worth exploring since
they could conceivably lead to the development of an
improved vaccine against this pathogen. The need to
develop such methodology is made palpable by the
unusual kinetics of the immune response to this virus,
as evidenced by the lack of a marked CMI response
upon vaccination and subsequent challenge with
virulent virus. The IFN-g response to PRRSV
therefore appears to be determined at the time of
the first exposure to this pathogen and is only
minimally affected by re-exposure. Although it is
also possible that we did not monitor the immune
response long enough post-challenge to detect a
significant increase in the number of virus-specific
IFN-g SC, this is unlikely since in the accompanying
manuscript a similar minimal enhancement was
observed when the immune response was measured
for up to 5 weeks after a booster immunization
(Royaee et al., 2004). In addition, similar limited
changes in the IFN-g response have been observed
upon challenge of vaccinated pigs with wild-type virus
(Foss et al., 2002) or booster immunization with MLV
vaccine (Meier et al., 2003). Remarkably, the T-cell
proliferative response to PRRSV was also not
W.A. Meier et al. / Veterinary Immunology and Immunopathology 102 (2004) 299–314310
increased by a booster immunization in pigs that had
previously been repeatedly exposed to a MLV vaccine,
but rather appeared to be suppressed as compared to
that elicited by the same vaccine in naı¨ve pigs
(Bassaganya-Riera et al., 2004). The mechanism
responsible for this unusual effect is currently
unknown, but might be related to the persistence of
the virus in lymphoid tissues associated with the site of
infection (Xiao et al., 2004). Such sustained presence
of virus could adversely affect a subsequent response
due to an inherent and yet unknown property of
PRRSV.
In summary, it is apparent that PRRSV elicits in
swine a polarized immune response characterized by
an abundance of non-neutralizing antibodies and a
paucity of IFN-g SC. The molecular pathway
responsible for generating this type of immunity is
unknown at this time, but based on the results
presented it likely involves the limited induction of
IFN-a and IL-12 production and/or inherent structural
elements of the virus that promote such a response. We
propose that the strong humoral immunity bias of the
host response to PRRSV is mostly responsible for the
difficulties in the development of a vaccine deemed
effective in the field. Although our use of porcine
cytokines, especially IFN-a, as adjuvants did not
radically affect PRRSV’s inherent ability to promote
this type of polarized immunity, a positive impact on
the transition of T lymphocytes to IFN-g SC was
noticed. The limited up-regulation of cellular IFN-g
responses (presented here) or gene expression
(described in the accompanying paper, Royaee
et al., 2004) indicates that more substantial stimulants
of innate immunity are to modify the host response to
PRRSV. Perhaps a more potent immunomodulator,
such as type A CpG oligodeoxynucleotides (Klinman,
2004), will overcome the tendency of PRRSV to
stimulate a strong non-neutralizing antibody response
and simultaneously promote a Th 1 (IFN-g domi-
nated) response.
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